Abstract. The most suitable treatment regimen for autoimmune hepatitis (AIH) in adults remains unknown and requires further investigation. The current study therefore aimed to integrate evidence to provide hierarchies of the comparative efficacies of treatments measured by clinical and biochemical remission. A Bayesian-framework network meta-analysis of randomized controlled trials (RCTs) was preformed to compare eight treatments for AIH. Eligible RCTs were identified by searching Embase, Pubmed and the Cochrane Library for publications between 1966 and April 2017. All outcomes were independently extracted from the included studies by two authors. A total of six RCTs were subsequently included in the current study. The network of comparisons on remission indicated that patients treated with prednisone (pred) experienced significantly increased rates of remission compared with those treated with azathioprine [AZA; odds ratio (OR), 0.21; 95% confidence interval (CI), 0.06-0.71] and budesonide (bude) + AZA significantly increased remission compared with placebo treatment (OR, 36.66; 95% CI, 1.40-962.49) or AZA (OR, 10.30; 95% CI, 1.50-70.70). Based on the cumulative ranking probabilities, bude + AZA (89.4) was ranked first, pred (69.1) was ranked second, pred + AZA (63.2) was ranked third and placebo (7.8) treatment was ranked last. Bude + AZA may be the most appropriate candidate for the treatment of non-cirrhotic patients. However, bude + AZA as frontline therapy for AIH requires more large-scale studies with a longer duration of follow-up histology and a focus on dose-response. Additionally, development of other prospective treatments, which may be used as alternative therapy or first line therapy, and their subsequent evaluation in clinical RCTs is required.

Introduction

Autoimmune hepatitis (AIH) manifests as inflammation of the liver with nonspecific symptoms, including fatigue, jaundice and arthralgia, and some patients may develop cirrhosis, which results in mortality due to liver failure or the need for liver transplantation (1). AIH may occur at all ages and is diagnosed more often in females, and it is increasingly recognized as a global disease (2). Prednisone (pred) treatment or pred plus azathioprine (AZA) treatment has been used as the conventional treatment for AIH for >40 years (3). However, some patients with AIH do not respond optimally to the standard treatment and those who do respond may experience strong side effects, including infection and diabetes mellitus, or a relapse following drug withdrawal (4). Thus, development of a novel alternative treatment for AIH is required.

Several medications, including cyclosporine-A (CsA), tacrolimus, mycophenolate mofetil, budesonide and ursodeoxycholic acid (UDCA) are emerging as alternative frontline therapies for patients with AIH (5-15). CsA, budesonide (bude) and UDCA have been evaluated by randomized clinical
trials (RCTs), and it has been demonstrated that they are just as effective or more effective than traditional treatment regimens (7,14,15). Other advances in the pharmacotherapy of AIH have been derived primarily from observational studies (5,8). Due to the low incidence of the disease in the general populations (mean annual incidence in white northern Europeans per 100,000 was 0.85-1.9 for AIH; point prevalence per 100,000 was 10.7-16.9 for AIH) (16,17), RCTs on the treatment of AIH are sparse and the number of patients included in RCTs is limited, leading to some potential interferences on conclusions. Therefore, the most effective treatment for AIH remains unclear.

The present study aimed to compare the efficacy of eight treatments, including pred, pred + AZA, pred in titrated doses given on alternate days (pred-T), placebo, AZA, budes + AZA, UDCA + pred and CsA for adult patients with AIH. These eight treatments were compared from six RCTs by network meta-analysis (NMA), which calculates the relative effects for all treatments, including treatments that have not been compared one by one, in the evidence network in one simultaneous analysis (18). The aim was to provide hierarchies of the comparative clinical and biochemical remission for eight treatments.

Materials and methods

Search methods. Embase (www.embase.com), Pubmed (www.ncbi.nlm.nih.gov/pubmed) and the Cochrane Library (www.cochranelibrary.com) databases were searched for publications published between 1966 and April 2017. Key words and Medical Subject Headings (the vocabulary thesaurus used for indexing articles for PubMed) terms including ‘Autoimmune Hepatitis’, ‘Hepatitis, Autoimmune’, ‘Autoimmune Chronic Hepatitis’, ‘Autoimmune Chronic Hepatitis’, ‘Chronic Hepatitis, Autoimmune’, ‘Hepatitis, Autoimmune Chronic,’ ‘Autoimmune Hepatitis’, ‘Chronic Hepatitis, Autoimmune’ and ‘Hepatitis, Autoimmune Chronic’, and ‘treatments and/or therapies’ were used during the search. The reference list for any discounted papers was also observed. Two reviewers independently made the selection of studies to include in the present study based on titles and abstracts. Any disagreement between reviewers was resolved by a further reviewer.

Inclusion and exclusion criteria. The selected studies had to fulfill the following inclusion criteria: i) Inclusion of patients with AIH; ii) inclusion of patients receiving therapeutic intervention; and iii) RCT study design that was randomized, placebo or an untreated controlled trial. Prior to the proposed definition of AIH by the International Autoimmune Hepatitis Group in 1993, there were evolving definitions of AIH (19). Therefore, in order to check whether the search performed included all published articles that were possibly associated with the present meta-analysis, the reference lists of included papers were also scrutinized.

Exclusion criteria included: i) Articles that were not written in English, German, French or Spanish; ii) studies including traditional Chinese medicine treatment; iii) studies evaluating the efficacy of therapy for AIH in children; iv) studies evaluating the efficacy of maintenance therapy for AIH; v) studies with a follow-up of <6 months; and vi) case studies, case series, review studies, letters and meeting proceedings.

Data collection. A total of two review authors screened papers, removed ineligible references and contacted corresponding authors if further information was required. If the article could not be provided, the data was obtained from the author or other associated articles. Information including the first author name, journal, study date range, sample size, comparators, treatment plan, country, study design, follow-up time and three outcomes (remission, mortality rates and adverse events) were extracted for each included study. Remission, mortality rates and adverse events were used to estimate efficacy and tolerability of treatments for the network meta-analysis.

Liver biopsy was not an outcome described in all articles, therefore, clinical and biochemical remission was applied as the primary outcome measure in order to achieve the most appropriate definition of remission for the study. The definition of clinical and biochemical remission was as follows, according to previously published studies: Aspartate aminotransferase and alanine transaminase (ALT) in the normal range and absence of any clinical signs of deterioration (14,15). All outcomes were extracted from the included studies and assessed at maximum follow-up.

Study quality. The Cochrane Risk of Bias Tool was used to assess the quality of included studies by two reviewers (20). The tool is based on assessing random sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting and other bias. The classification of the judgment for each domain was low risk of bias, unclear risk of bias or high risk of bias.

Data analysis. A traditional pairwise meta-analysis, which directly compared different treatments, was first performed using Stata software (version 13.0; StataCorp, College Station, TX, USA). According to the Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, the pooled estimates of hazard ratios (HRs), odds ratios (ORs) and 95% confidence intervals (CIs) of remission were calculated using the DerSimonian and Laird random-effects model. A χ² square test and I² test were used for testing heterogeneity among the studies. If the OR and 95% CI were not close to 1, there was a statistical difference between the two groups. P<0.05 indicated that the difference between groups was statistically significant.

The network meta-analysis was also performed using Stata software with the random effects models proposed by Chaimani et al (21) (downloaded from mtm.uoi.gr) according to the program. The ifplot command was used to evaluate the consistency of direct and indirect estimates. A funnel plot was used to identify possible publication bias if the number of RCTs was >10 (22). Posterior probabilities of outcomes were used to calculate probabilities of treatment ranking and the cumulative ranking probabilities (surface under the cumulative ranking curve; SUCRA) were used to indicate the most effective treatment.

Results

Study identification and selection. A PRISMA flow diagram of study selection is presented in Fig. 1. The search was performed on April 17 2017 and 9,761 references were identified. Following
removal of 4,828 duplicate references, 4,933 records were screened. However, 4,877 articles were excluded following review of the title and abstract (e.g., studies not associated with AIH). A total of 56 studies were included in the narrative review and data from six of these studies were included in the meta-analysis. A total of 50 studies were excluded due to 34 studies not being RCT studies, four studies evaluating the efficacy of therapy for AIH in children (23-26), six studies evaluating maintenance therapy for AIH (27-31), two studies evaluating traditional Chinese medicine treatment (32,33), one study being unable to extract any reliable data (34), two studies not reporting the outcome that met inclusion criteria (9,11) and one study where treatment duration was indefinite and may have included the same relapsed patients with AIH as those included in another study performed by the same author (6).

Study characteristics. Table I provides a summary of the studies included in the present review. A total of six studies were included, with a total of 517 patients. All studies were RCTs directly comparing alternative treatments. A total of
Table I. Characteristics of included studies.

| Author, year | Journal | Study design | Patients | Age, years (mean ± SD) | Intervention | Maximum follow-up | Study size (n) | Remission (n) | (Refs.) |
|--------------|---------|--------------|----------|------------------------|--------------|--------------------|----------------|---------------|---------|
| Soloway et al, 1972 | Gastroenterology | RCT | Naïve or relapse AIH | 44.0±7.1 | Pred: 60 mg/day for 1 week; 40 mg/day for 1 week; 30 mg/day for 2 weeks; 20 mg/day for maintenance | 42 months | 18 | 8 | (10) |
| | | | | | AZA: 100 mg/day | | | | |
| | | | | | AZA (50 mg/day) + Pred: 30 mg/day for 1 week; 20 mg/day for 1 week; 15 mg/day for 2 weeks; 10 mg/day for maintenance | 14 | 1 |
| | | | | | Placebo | 17 | 0 |
| Summerskill et al, 1975 | Gut | RCT | Naïve AIH | 40.0±3.6 | Pred: 60 mg/day for 1 week; 40 mg/day for 1 week; 30 mg/day for 2 weeks; 20 mg/day for maintenance | 36 months | 30 | 14 | (12) |
| | | | | | AZA (50 mg/day) + Pred: 44.0±3.5 | 30 | 17 |
| | | | | | Placebo: 38.0±3.5 | - | - |
| | | | | | AZA: 100 mg/day | - | - |
| | | | | | Pred-T: 34.0±2.6 | 31 | 9 |
| Tage-Jensen et al, 1982 | Liver | RCT | Naïve AIH | 67.0 (25.0-80.0)a | AZA: 10 mg/kg/week for first 2 weeks and then 5 mg/kg/week Pred: <70 kg, 10 mg/day; ≥70 kg 15 mg/day | 83 months | 37 | 6 | (13) |
| Czaja et al, 1999 | Hepatology | RCT | Relapse AIH | 42.0±2.0 | UDCA (13-15 mg/kg/day) + Pred: 60 mg/day for 1 week; 40 mg/day for 1 week; 30 mg/day | 6 months | 21 | 3 | (7) |
Table I. Continued.

| Author, year     | Journal                        | Study design | Patients                  | Age, years (mean ± SD) | Intervention                                                                 | Maximum follow-up | Study size (n) | Remission (n) | (Refs.) |
|------------------|--------------------------------|--------------|---------------------------|------------------------|------------------------------------------------------------------------------|--------------------|----------------|--------------|---------|
| Manns et al, 2010| Gastroenterology               | RCT          | Naïve or relapse AIH      | 36.0±17.0              | Pred: 60 mg/day for 1 week; 40 mg/day for 1 week; 30 mg/day for 2 weeks; 20 mg/day for maintenance | 6 months           | 100            | 60           | (14)    |
|                  |                                |              |                           | 50.0±4.0               | Pred: 60 mg/day; Bude: 3 mg three times daily or 3 mg twice daily, after biochemical remission + AZA 1-2 mg/kg/day |                    | 16             | 3            |
| Siavosh et al, 2013 | Middle East                   | RCT          | Naïve AIH                 | 33.6±12.7              | Pred: Starting dose 40 mg/day tapered to 10 mg/day + AZA 1-2 mg/kg/day | 12 months          | 24             | 12           | (15)    |
|                  | Journal of Digestive Diseases |              |                           | 30.0±10.3              | Cyclosporine-A: 2 mg/kg body weight in two divided doses administered orally 12 h apart |                    | 15             | 7            |

*Age, mean (range); SD, standard deviation; n, number; AIH, autoimmune hepatitis; RCT, randomized controlled trial; pred, prednisone; pred-T, prednisone in titrated doses given on alternate days; AZA, azathioprine; bude, budesonide; UDCA, ursodeoxycholic acid.*
four out of six studies were two-grouped studies, one was a four-grouped study and one was a five-grouped study. These studies were published between 1972 and 2013. The treatment duration was between 6 months and 6 years and the mean age of participants was 41.5 years. A total of eight treatments were included in the network meta-analysis with no treatment considered as placebo treatment. A total of six studies reported clinical and biochemical remission as the outcome.

Risk of bias in included studies. The risk of bias in all six studies is presented in Fig. 2. A total of six studies (100%) described random sequence generation and adequate allocation concealment (100%). A total of four studies (67%) described blinding of participants and personnel, and three studies (50%) had low risk of blinding of outcome assessment. A total of two studies (33%) had a low risk of incomplete outcome data and one study (16%) had low risk of selectively reporting results. Although some studies had dropout, the effect of intervention was not affected due to the small scale of dropout.

Effects of treatments on remission. A total of 147 patients were assigned to pred + AZA treatment, 135 to pred therapy, 100 to bude + AZA therapy, 51 to AZA therapy, 31 to pred-T therapy, 21 to UDCA + pred therapy, 17 to placebo therapy and 15 to CsA therapy.

The direct comparisons on remission were performed in Table II. The result indicated that patients treated with pred had significantly increased rates of remission compared with patients treated with AZA (OR, 0.20; 95% CI, 0.08 -0.53) or placebo (OR, 0.04; 95% CI, 0.00 -0.68) and patients treated with pred + AZA had a significantly increased rate of remission compared with those treated with pred-T (OR, 0.31; 95% CI, 0.11-0.90). In addition, patients treated with bude + AZA had a significantly increased rate of remission compared with those treated with pred + AZA (OR, 2.36; 95% CI, 1.35-4.15).

The network of comparisons on remission is presented in Fig. 3 and Table II. Treatment with pred significantly increased remission compared with treatment with AZA (OR, 0.21; 95% CI, 0.06-0.71) and bude + AZA treatment significantly increased remission compared with placebo treatment.

Table II. Direct comparisons or network meta-analysis of the remission of different treatments.

| Treatment | Pred | Pred + AZA | Pred-T | Placebo | AZA | Bude + AZA | UDCA + Pred | CsA |
|-----------|------|------------|--------|---------|-----|------------|-------------|-----|
| Pred      | 0.89 (0.31, 2.56) | 0.47 (0.16, 1.35) | 0.04 (0.00, 0.69) | 0.28 (0.03, 2.11) | 3.89 (0.15, 103.19) | 10.30 (150, 70-70) | 3.49 (0.23, 35-60) | 0.41 (0.03-4.0) |
| Pred + AZA| 0.90 (0.28-2.88) | 0.36 (0.09, 1.44) | 0.60 (0.00, 1.39) | 0.16 (0.01, 3.42) | 0.56 (0.16, 78.85) | 10.02 (460, 0.62-49) | 0.34 (0.03,4.40) | 0.44 (0.03-3.99) |
| Pred-T    | 0.31 (0.11, 0.90) | 0.06 (0.00, 1.16) | 0.23 (0.05, 1.19) | 0.57 (0.09, 3.42) | 3.56 (0.16, 78.85) | 10.02 (460, 0.62-49) | 0.34 (0.03,4.40) | 0.44 (0.03-3.99) |
| Placebo   | 0.06 (0.00, 0.71) | 0.36 (0.07, 1.68) | 2.36 (0.78, 7.20) | 5.87 (1.00, 34.44) | 12.40 (0.34, 45.2-42) | 4.29 (0.23, 35-60) | 0.04 (0.00,0.00) | 0.24 (0.02-19.97) |
| AZA       | 2.14 (0.43, 10.68) | 0.38 (0.06, 8.60) | 5.87 (1.00, 34.44) | 1.98 (0.18, 22.44) | 4.29 (0.23, 35-60) | 15.02 (0.30, 4-48-64) | 0 (1.00, 0.00) | 2.40 (0.29-19.97) |
| Bude + AZA| 0.72 (0.30, 1.83) | 0.97 (0.33, 2.98) | 1.98 (0.18, 22.44) | 2.40 (0.29-19.97) | 15.02 (0.30, 4-48-64) | 4.29 (0.23, 35-60) | 0 (1.00, 0.00) | 2.40 (0.29-19.97) |
| UDCA + Pred| 0.88 (0.17, 4.38) | 0.97 (0.13, 7.44) | 4.29 (0.23, 35-60) | 2.40 (0.29-19.97) | 15.02 (0.30, 4-48-64) | 4.29 (0.23, 35-60) | 0 (1.00, 0.00) | 2.40 (0.29-19.97) |
| CsA       | 0.88 (0.17, 4.38) | 0.97 (0.13, 7.44) | 15.02 (0.30, 4-48-64) | 2.40 (0.29-19.97) | 15.02 (0.30, 4-48-64) | 4.29 (0.23, 35-60) | 0 (1.00, 0.00) | 2.40 (0.29-19.97) |

For remission, data as presented as the odds ratio (95% confidence interval) was calculated. Direct comparisons indicate the comparison between the two two-treatment networks (pred-T). Pred, prednisone; AZA, azathioprine; pred-T, prednisone in titrated doses given on alternate days; bude, budesonide; UDCA, ursodeoxycholic acid; SUCRA, surface under the cumulative ranking curve; PrBest, probability of being the best treatment.

Table III. SUCRA and rank results.

| Treatment      | SUCRA | PrBest | Mean rank |
|----------------|-------|--------|-----------|
| Pred           | 69.1  | 6.3    | 3.2       |
| Pred + AZA     | 63.2  | 1.6    | 3.6       |
| Pred-T         | 33.0  | 0.6    | 5.7       |
| Placebo        | 7.8   | 0.5    | 7.5       |
| AZA            | 18.6  | 0.0    | 6.7       |
| Bude + AZA     | 89.4  | 59.2   | 1.7       |
| UDCA + pred    | 56.1  | 16.4   | 4.1       |
| Cyclosporine-A | 62.8  | 15.4   | 3.6       |

Pred, prednisone; AZA, azathioprine; pred-T, prednisone in titrated doses given on alternate days; bude, budesonide; UDCA, ursodeoxycholic acid; SUCRA, surface under the cumulative ranking curve; PrBest, probability of being the best treatment.
(OR, 36.66; 95% CI, 1.40-962.49) or AZA (OR, 10.30; 95% CI, 1.50-70.70). A ranking graph of distribution of probabilities on remission is presented in Fig. 4A. Based on SUCRA, bude + AZA treatment (89.4) was ranked first, pred (69.1) was ranked second, pred + AZA (63.2) and CsA (62.8) were ranked fourth and placebo was ranked last (7.8; Table III).

Inconsistency test. Inconsistency refers to differences between direct and various indirect effect estimates for the same comparison. The ratio of two odds ratios (RoR) from direct and indirect evidence in each loop was calculated to estimate the inconsistency. RoR values close to 1 mean that the direct and indirect evidence were in agreement.

Fig. 4B demonstrated that in a total of four loops there were none with statistically significant inconsistency (all CIs for RoRs were compatible with zero inconsistency (RoR=1). These results indicate that direct and indirect estimates were consistent with one another.

Publication biases. Publication bias was not assessed because the number of RCTs was limited (<10).

Other outcomes. The frequencies and percentages of adverse events were not recorded in the majority of articles (Table IV). Adverse events associated with pred and bude treatment were as follows: Cushingoid appearances, including moon face, acne and hirsutism; diabetes mellitus; hypertension; and cataracts. The adverse events following AZA therapy were gastrointestinal bleeding, leucopenia, trombopenia and arthralgia. Combination therapy with pred + AZA exhibited a markedly lower reported frequency of adverse events compared with pred monotherapy (data not shown). In addition, bude treatment had less adverse events compared with pred treatment (data not shown).

Table IV revealed the mortalities for all included studies. The direct comparisons on mortality were presented in Table V. The results indicated that patients treated with pred had significantly decreased rates of mortality compared with patients treated with the placebo (OR, 0.14; 95% CI, 0.04-0.52). No significant differences in the mortality rates were identified between patients treated with pred and those treated with pred-T (OR, 1.61; 95% CI, 0.25-10.40), AZA (OR, 0.29; 95%
| Author, year | Journal | Intervention | Treatment duration | Patients (n) | Adverse events (n) | Mortalities (n) | (Refs.) |
|-------------|---------|--------------|--------------------|-------------|--------------------|----------------|--------|
| Soloway et al, 1972 | Gastroenterology | Pred: 60 mg/day for 1 week; 40 mg/day for 1 week; 30 mg/day for 2 weeks; 20 mg/day maintenance | 3 months-3.5 years | 18 | Cushingoid appearance (13), diabetes requiring insulin (1), GI-bleeding (1), spinal collapse, aseptic necrosis of hip or cataracts (3) | 1 | (10) |
| | | AZA: 100 mg/day | | 14 | | | |
| | | AZA (50 mg/day) + Pred: 30 mg/day for 1 week; 20 mg/day for 1 week; 15 mg/day for 2 weeks; 10 mg/day for maintenance | | 14 | Cushingoid appearance (2), GI-bleeding (3), spinal collapse, aseptic necrosis of hip or cataracts (1), leucopenia/thrombocytopenia (2), ascites + 2 x increase in bilirubin (>6 mg/100 ml) (2) | 5 | |
| | | Placebo | | 17 | None | 7 | |
| Summerskill et al, 1975 | Gut | Pred: 60 mg/day for 1 week; 40 mg/day for 1 week; 30 mg/day for 2 weeks; 20 mg/day maintenance | 36 months | 30 | Severe cosmetic changes (5), diabetes (6), cataracts (5), hypertension (3), duodenal ulcer (1), steroid psychosis (2), aseptic necrosis of hip (1), vertebral collapse (1), haematemesis (1) | 3 | (12) |
| | | AZA (50 mg/day) + Pred: 30 mg/day for 1 week; 20 mg/day for 1 week; 15 mg/day for 2 weeks; 10 mg/day for maintenance | | 30 | Diabetes mellitus (3), haematemesis (1), skin rash (2), cacinoma (bladder) (1), thrombocytopenia (3) | 2 | |
| | | AZA: 100 mg/day | | 13 | - | 6 | |
| | | Placebo | | 16 | None | 6 | |
| | | Pred-T | | 31 | Severe cosmetic changes, diabetic mellitus cataracts, hypertension | 2 | |
| Author, year          | Journal                      | Intervention                                    | Treatment duration | Patients (n) | Adverse events (n)                                                                 | Mortalities (n) | Refs. |
|----------------------|------------------------------|-----------------------------------------------|-------------------|-------------|--------------------------------------------------------------------------------|----------------|-------|
| Tage-Jensen et al, 1982 | Liver                        | AZA: 10 mg/kg/week for the first 2 weeks and then 5 mg/kg/week Pred: <70 kg 10 mg/day, ≥70 kg 15 mg/day | 38 (12-83) months | 37          | -                                                                              | 10             | (13)  |
| Czaja et al, 1999    | Hepatology                   | UDCA (13-15 mg/kg/day) + Pred: 60 mg/day for 1 week; 40 mg/day for 1 week; 30 mg/day for 2 weeks; 20 mg/day for maintenance Pred: 60 mg/day for 1 week; 40 mg/day for 1 week; 30 mg/day for 2 weeks; 20 mg/day for maintenance | 6 months          | 21          | -                                                                              | 1              | (7)   |
| Manns et al, 2010    | Gastroenterology             | Bude: 3 mg three times daily or 3 mg twice daily, after biochemical remission + AZA 1-2 mg/kg/day Pred: starting dose 40 mg/day tapered to 10 mg/day + AZA 1-2 mg/kg/day | 6 months          | 100         | Moon face (10), acne (8), hirsutism (9), skin striae (2), buffalo hump (1), diabetes (4) | 0              | (14)  |
| Nasseri-Moghaddam et al, 2013 | Middle East Journal of Digestive Diseases | Pred: 50 mg/day CsA: 2 mg/kg body weight in two divided doses administered orally 12 h apart | 12 months         | 24          | -                                                                              | 2              | (15)  |

Pred, prednisone; AZA, azathioprine; pred-T, prednisone in titrated doses given on alternate days; bude, budesonide; UDCA, ursodeoxycholic acid; CsA, cyclosporine-A; GI, gastrointestinal; n, number.
CI, 0.06-1.51), UDCA + pred (OR, 0.41; 95% CI, 0.02-10.85) and CsA (OR, 3.44; 95% CI, 0.15-76.81). In addition, patients treated with pred + AZA had significantly decreased rates of mortality compared with patients treated with the placebo (OR, 0.12; 95% CI, 0.03-0.46) and AZA (OR, 0.10; 95% CI, 0.02-0.42). No significant differences in the mortality rates were identified between patients treated with pred + AZA and those treated with pred-T (OR, 1.04; 95% CI, 0.14-7.87), bude + AZA (OR, 0.97; 95% CI, 0.06-15.74). No statistical differences of mortality rate were identified between AZA therapy and placebo treatment (data not shown).

Table V. Mortality rates of different treatments.

| Treatment | Pred-T | Placebo | AZA | Bude + AZA | UDCA + Pred | CsA |
|-----------|--------|---------|-----|------------|-------------|-----|
| Pred      | 1.61 (0.25, 10.40) | 0.14 (0.04, 0.52)* | 0.29 (0.06, 1.51) | -           | 0.41 (0.02, 10.85) | 3.44 (0.15, 76.81) |
| Pred + AZA | 1.04 (0.14, 7.87) | 0.12 (0.03, 0.46)* | 0.10 (0.02, 0.42)* | 0.97 (0.06, 15.74) | -           | -   |

For mortality rates, data as presented as the odds ratio (95% confidence interval) was calculated. If the OR and 95% CI were not close to 1, there was a statistical difference between the two treatments (P<0.05). *Significant difference between two treatments. Pred, prednisone; AZA, azathioprine; pred-T, prednisone in titrated doses given on alternate days; bude, budesonide; UDCA, ursodeoxycholic acid; CsA, cyclosporine-A.

Discussion

The network meta-analysis performed in the present study provided hierarchies of treatments for clinical and biochemical remission in adult patients with AIH. The meta-analysis demonstrated that the remission of patients was significantly increased following treatment with pred compared with AZA and was significantly increased following treatment with bude + AZA compared with placebo or AZA. Direct comparison demonstrated that remission of patients was significantly increased following treatment with pred compared with AZA or placebo treatment and similarly, remission of patients was significantly increased following treatment with pred + AZA compared with pred-T treatment. In addition, direct comparison indicated that patient remission was significantly increased following treatment with bude + AZA compared with pred + AZA. Treatments were ranked for increasing remission as follows: Bude + AZA, pred, pred + AZA or CsA, UDCA + pred, pred-T, AZA and placebo. Direct comparisons indicated that the frequency of adverse events in patients treated with pred + AZA combination therapy was decreased compared with that in patients treated with pred monotherapy, and patients treated with bude experienced fewer adverse events compared with those treated with pred alone. Furthermore, direct comparisons also demonstrated that the mortality of patients who underwent AZA or placebo treatment was increased compared with that of patients who underwent treatment with pred or pred + AZA; however, there was no notable difference between other treatments and pred or pred + AZA treatment.

The present study has a range of strengths: i) The search strategy was comprehensive in order to decrease the possibilities of publication bias; ii) only RCTs without high risk of bias were included in the current study; iii) network meta-analysis was used in the current study, which produces direct and indirect evidence in a network of trials that compare multiple interventions; and iv) the eight treatments included in the study were ranked based on the posterior probabilities of outcomes and SUCRA.

However, there are also limitations to the current study. The results were affected by study characteristics, including sex, detection bias and performance bias. In addition, the primary outcome measures did not include histological remission and may have an impact on the assessment of treatment efficacy, and an evolving set of diagnostic criteria may affect the objectivity of the results.

Pred alone or in combination with AZA was demonstrated to be more effective compared with AZA or placebo monotherapy in early studies, and therefore has become the standard therapy used to treat patients with AIH (35). Furthermore, treatment with pred + AZA had fewer adverse events compared with pred treatment alone (35,36), which was consistent with the results of the current study. Bude therapy in combination with AZA has now emerged as an alternative frontline therapy for classical therapy in AIH (37-39). Through random experiments, Woynarowski et al (24) also discovered that bude may be an alternative to standard pred therapy in children. However, Czaja and Lindor (40) demonstrated that bude therapy had a low frequency of remission in ten treatment-dependent patients with AIH. Peiseler et al (41) also demonstrated that the efficacy of bude therapy may be lower compared with that of pred therapy alone; however, this effect may have been caused by the different study populations used. Danielsson and Prytz (42) indicated that oral bude therapy decreased liver inflammation in patients with non-cirrhotic AIH only. The network analysis in the current study ranked bude + AZA as higher than pred + AZA. Furthermore, descriptive analysis indicated that patients undergoing bude treatment experienced fewer adverse events compared with those who underwent pred treatment alone. The study population of included RCTs focusing on bude + AZA treatment was patients with non-cirrhotic AIH, and other studies did not distinguish between cirrhotic and non-cirrhotic patients. Therefore, further large-scale studies with a longer duration of follow-up history and a focus on dose response are required to investigate the use of bude + AZA as frontline therapy in adults with AIH. However, the results of the current study suggest that bude + AZA may be the most appropriate candidate for treatment of non-cirrhotic patients, which is consistent with the results demonstrated by Czaja (43).

The results of the current study demonstrated that treatment with CsA, UDCA + pred or pred-T resulted in increased...
remission rates compared with that observed in patients who received placebo treatment. Treatment with CSA, UDCA + pred or pred-T also had the same mortality rate as standard therapy. Thus, these therapies may be used as alternative treatment in patients with AIH who cannot undergo classical therapy. No statistical differences of mortality rate were identified between AZA therapy and placebo treatment; therefore, AZA is not recommended for treatment of patients with AIH, which is consistent with the conclusions provided by Gleeson (35).

It has been demonstrated that mycophenolate mofetil (MMF) (5,44-51), methotrexate (52), 6-mercaptopurine (53), allopurinol (54,55), tacrolimus (8,45,56-59) and everolimus (60) are effective and well-tolerated in patients with AIH. Torisu et al (61) indicated that UDCA monotherapy may be considered for treatment of patients with AIH with a serum ALT level of <200 IU/l. Among these treatments, MMF and tacrolimus were the most studied. Efe et al (62) also demonstrated that tacrolimus was more effective compared with MMF as therapy for difficult-to-treat AIH. In addition, MMF (63), calcineurin inhibitors (64,65), sirolimus (66,67), denosumab (68), rituximab (69) and infliximab (70) have been used successfully as salvage therapies in small observational studies. Although these therapies have been effective as treatment for patients with AIH, their superiority to standard treatment has not been evaluated. Therefore, clinical RCTs are required. Cytotoxic T lymphocyte antigen-4 (71), non-mito-
genic antibodies to cluster of differentiation 3 (72), regulatory T cell promoters (73,74), natural killer T cell modulators (75), anti-fibrotic agents (76), monoclonal antibodies or nanobodies to chemokines (77) and anti-apoptotic agents (78) have been proposed for the treatment of autoimmune disease and may be novel alternative treatments for AIH; however, this requires further study.

In conclusion, the results of the present study based on rela-
tively small numbers suggest that treatment with pred alone or in combination with AZA remain the standard treatment for AIH. Bude in combination with AZA may be the most appropriate treatment for non-cirrhotic patients. However, bude + AZA as frontline therapy in adults with AIH requires additional large-scale studies with a longer duration of follow-up histology and a focus on dose-response. Additionally, development of other prospective treatments, which may be used as alternative therapies or first line therapies, and their subsequent evaluation in clinical RCTs is required.

Acknowledgements

The authors wish to thank members of Wenzhou Key Labor-
atory of Hepatology and the Hepatology Institute of Wenzhou Medical University for technical assistance. The present study was supported by the National Natural Science Foundation of China (grant nos. 81570514 and 81500477); Natural Science Foundation of Zhejiang Province (grant no. LY15H030017 and LQ15H030006); Public Welfare Science and Technology Project of Wenzhou (grant no. Y201500014); Medical Award Fund (Beijing, China; grant no. YJHYXKYJJ-162); Scientific and Technological Innovation Team of the Early Warning and Intervention to End-stage Liver Disease of Wenzhou (grant no. C20150005); and the National Major Scientific and Technological Special Project during the Twelfth Five-year Plan Period (China; grant nos. 2013ZX100050002-001-008, 2013ZX10002003 and 2012ZX10002004).

References

1. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D and Vierling JM: American Association for the Study of Liver Diseases: Diagnosis and management of autoimmune hepatitis. Hepatology 51: 2193-2213, 2010.
2. Heneghan MA, Yeoman AD, Verma S, Smith AD and Longhi MS: Autoimmune hepatitis. Lancet 382: 1433-1444, 2013.
3. Gleeson D and Heneghan MA: British Society of Gastroenterology: British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 60: 1611-1629, 2011.
4. Selvarajah V, Montano-Loza AJ and Czaja AJ: Systematic review: Managing suboptimal treatment responses in autoim-
mune hepatitis with conventional and non-standard drugs. Aliment Pharmacol Ther 36: 691-707, 2012.
5. Zachou K, Gatselis N, Papadamou G, Rigopoulos EI and Dalekos GN: Mycophenolate for the treatment of autoimmune hepatitis: Prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. J Hepatol 55: 636-646, 2011.
6. Czaja AJ, Wang KK, Shielis MT and Katzmann JA: Oral pulse prednisone therapy after relapse of severe autoimmune chronic active hepatitis. A prospective randomized treatment trial evaluating clinical, biochemical, and lymphocyte subset responses. J Hepatol 17: 180-186, 1993.
7. Czaja AJ, Carpenter HA and Lindor KD: Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: A randomized placebo-controlled treatment trial. Hepatology 30: 1381-1386, 1999.
8. Van Thiel DH, Wright H, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, McMichael J, Irish W and Starzl TE: Tacrolimus: A potential new treatment for autoimmune chronic active hepatitis: Results of an open-label preliminary trial. Am J Gastroenterol 90: 771-776, 1995.
9. Cook GC, Mulligan R and Sherlock S: Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. J Med 40: 159-185, 1971.
10. Soloway RD, Summerskill WH, Baggenstoss AH, Geall MG, Gittnick GL, Elveback IR and Schoenfield LJ: Clinical, biochem-
ical, and histological remission of severe chronic active liver disease: A controlled study of treatments and early prognosis. Gastroenterology 63: 820-833, 1972.
11. Murray-Lyon IM, Stern RB and Williams R: Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1: 735-737, 1973.
12. Summerskill WH, Korman MG, Ammon HV and Baggenstoss AH: Prednisone for chronic active liver disease: Dose titration, standard dose, and combination with azathioprine compared. Gut 16: 876-883, 1975.
13. Tagge-Jensen U, Schlichting P, Aldershvile J, Andersen P, Dietrichson O, Hardt F, Mathiesen LR and Nielsen JO: Azathioprine versus prednisone in non-alcoholic chronic liver disease (CLD). Relation to a serological classification. Liver 2: 95-103, 1982.
14. Manns MP, Woynarowski M, Kreisel W, Lurie Y, Rust C, Zackerman E, Bah M, Günther R, Hultcrantz RW, Spengler U, et al: Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 139: 1198-1206, 2010.
15. Nasserri-Moghaddam S, Nikfam S, Karimian S, Khashayar P and Malekzadeh R: Cyclosporine-a versus prednisolone for induction of remission in auto-immune hepatitis: Interim analysis report of a randomized controlled trial. Middle East J Dig Dis 5: 193-200, 2013.
16. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M and Bell H: Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 33: 99-103, 1998.
17. Werner M, Frytz H, Olsson B, Almer S, Björnsson E, Bergquist A, Wallerstedt S, Sandberg-Gertzén H, Hultcrantz R, Sangleit E, et al: Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: A nationwide study. Scand J Gastroenterol 43: 1232-1240, 2008.


4849

41. Peiseler M, Liebscher T, Pannnicke N, Sebode M, Zenouzi R, Hartl J, Eh lken H, Weiler-Norman C, Lohse AW and Schramm C: Budesonide for autoimmune hepatitis: Response rate and limitation in a large real life cohort. J Hepatol 62 (Suppl 2): S233, 2015.

42. Danielsson A and Prytz H: Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 8: 385-590, 1994.

43. Czaja AJ: Current and prospective pharmacotherapy for autoimmune hepatitis. Expert Opin Pharmacother 15: 1715-1736, 2014.

44. Anderka MT, Lin AE, Abue lo DN, Mitchell AA and Rasmussen SA: Reviewing the evidence for mycophenolate mofetil as a new teratogen: Case report and review of the literature. Am J Obstet Gynecol 198: 1241-1248, 2008.

45. Efe C, Hagstroim H, Bajani RA, Müller NF, Wang Q, Purnak T, Muratori L, Werner M, Marschall HU, Muratori P, et al: Tacrolimus or mycophenolate mofetil as a second-line therapeutic options in patients with Autoimmune Hepatitis: An international multicentre observational study. AASLD 62: 109552, 2015.

46. Zachou K, Gatselis N, Gabela S, Saitis A, Koukoulis G and Dalekos GN: P1138: Long-term outcome of patients with autoimmune hepatitis receiving mycophenolate mofetil (MMF) as first line treatment. J Hepatol 62 (Suppl 2): S778-S779, 2015.

47. Gazzola A, Lim R, Strasser S, Ricci A, Mitchell J, Siow W, Khoo T, Hamarneh Z, Weltman M, Janko N, et al: Mycophenolate in autoimmune hepatitis not responsive or intolerant to standard therapy: The TAPPESTRY study. J Gastroenterol Hepatol (Australia) 31: 100-101, 2016.

48. Gazzola A, Lim R, Strasser SJ, Nicolli A, Mitchell J, Siow W, Khoo TS, Hamarneh Z, Weltman M, Janko N, et al: Mycophenolate in autoimmune hepatitis patients not responsive or intolerant to standard therapy: The TAPPESTRY study. J Hepatology 63: 817A, 2016.

49. Kostyrok O, Shumbala P and Shigoleva N: Mycophenolate mofetil for the treatment of autoimmune hepatitis in children. J Hepatol 64: S640, 2016.

50. Park SW, Um SH, Lee HA, Kim SH, Sim Y, Yim SY, Seo YS and Ryu HS: Mycophenolate mofetil as an alternative treatment for children with autoimmune hepatitis. J Pediatr Gastroenterol Nutr 63: S56, 2016.

51. Haridy J, Nicolli A and Sood S: Methotrexate therapy for autoimmune hepatitis. Clin Gastroenterol Hepatol 17: 22-26, 2019.

52. Hübener S, Oo YH, Than NN, Hübener P, Weiler-Norman C, Lohse AW and Schramm C: Eficacy of 6-mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance. Clin Gastroenterol Hepatol 14: 445-453, 2016.

53. Deswal S and Srivastava A: Role of allopurinol in optimizing mycophenolate therapy: A prospective study. J Clin Exp Hepatol 6 (Suppl 2): 118-126, 2016.

54. Zachou K, Gatselis NK, Arvaniti P, Batsela S, Rigopoulos EL, Koukoulis G and Dalekos GN: A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis. Aliment Pharmacol Ther 43: 1035-1047, 2016.

55. Haridy J, Nicolli A and Sood S: Methotrexate therapy for autoimmune hepatitis. Clin Gastroenterol Hepatol 17: 12, 2019 (Epub ahead of print).

56. Plawiak W and Romsing J: Evaluation of allopurinol in patients with autoimmune hepatitis. Clin Exp Immunol 124: 142-147, 2001.

57. Than NN, Wiegard C, Mann JF, Fussel K, Hirschfield GM, Lohse AW, Adams D, Schramm C and Oo YH: Allopurinol is safe and effective to achieve biochemical and histological remission in patients with autoimmune hepatitis with incomplete therapeutic response. J Hepatol 64 (Suppl): S435, 2016.

58. Alkhouri N: The use of tacrolimus in refractory autoimmune hepatitis. World J Gastroenterol 23: 2822-2828, 2017.

59. Lai K, Willemsen M, Mullen L, de Caux JF, Greenberg NM, Schinella RS, Zucchetti A, Taurisano P, et al: Immunosuppression in children with autoimmune hepatitis: A real-world experience. J Pediatr Gastroenterol Nutr 63: 210-216, 2016.

60. Zachou K, Gatselis NK, Arvaniti P, Gatselis P, Rigopoulos EL, Koukoulis G and Dalekos GN: A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis. Aliment Pharmacol Ther 43: 1035-1047, 2016.
6. Torisu Y, Nakano M, Takano K, Nakagawa R, Saeki C, Hokari A, Ishikawa T, Saruta M and Zeniya M: Clinical usefulness of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis. World J Hepatol 9: 57-63, 2017.

62. Efe C, Hagstrom H, Yting H, Bhanji RA, Müller NF, Wang Q, Purnak T, Muratori L, Werner M, Marschall HU, et al: Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis. Clin Gastroenterol Hepatol 15: 1950-1956, 2017.

63. Baven-Pronk AM, Coenraad MJ, van Buuren HR, de Man RA, van Erpecum KJ, Lamers MM, Drenth JP, van den Berg AP, Beuers UH, den Ouden J, et al: The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther 34: 335-343, 2011.

64. Czaja AJ: Autoimmune hepatitis: Focusing on treatments other than steroids. Can J Gastroenterol 26: 615-620, 2012.

65. Czaja AJ: Drug choices in autoimmune hepatitis: Part B-Nonsteroids. Expert Rev Gastroenterol Hepatol 6: 617-635, 2012.

66. Kurowski J, Melin-Aldana H, Bass L, Alonso EM and Ekong UD: Sirolimus as rescue therapy in pediatric autoimmune hepatitis. J Pediatr Gastroenterol Nutr 58: e4-e6, 2014.

67. Chatrath H, Allen L and Boyer TD: Use of sirolimus in the treatment of refractory autoimmune hepatitis. Am J Med 127: 1128-1131, 2014.

68. Ikejima K, Yaginuma R, Kon K, Aoyama T, Uchiyama A, Yamashina S and Watanabe S: Efficacy of denosumab on progression of osteoporosis in autoimmune liver diseases. Hepatol (Baltimore, Md) 63: 201A, 2016.

69. Gautam N, Than NN, Nizamuddin M, Adams D and Oo YH: PTU-123 use of rituximab in resistant autoimmune hepatitis-Birmingham experience. Gut 63: A93, 2014.

70. Weiler-Normann C, Schramm C, Quaas A, Wiegard C, Glaubke C, Pannicke N, Möller S and Lohse AW: Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol 58: 529-534, 2013.

71. Dhirapong A, Yang GX, Nadler S, Zhang W, Tsuneyama K, Leung P, Knechtle S, Ansari AA, Coppel RL, Liu FT, et al: Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology 57: 708-715, 2013.

72. Killestein J: Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 347: 1116-1117, 2002.

73. Czaja AJ: Challenges in the diagnosis and management of autoimmune hepatitis. Can J Gastroenterol 27: 531-539, 2013.

74. Lapierre P, Béland K, Yang R and Alvarez F: Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance. Hepatology 57: 217-227, 2013.

75. Blumenfeld HJ, Tohn R, Haeryfar SM, Liu Y, Savage PB and Delovitch TL: Structure-guided design of an invariant natural killer T cell agonist for optimum protection from type 1 diabetes in non-obese diabetic mice. Clin Exp Immunol 166: 121-133, 2011.

76. Czaja AJ: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis (Review). Aliment Pharmacol Ther 39: 385-406, 2014.

77. Yellin M, Paliienko I, Balanescu A, Ter-Vartanian S, Tseluyko V, Xu LA, Tao X, Cardarelli PM, Leblanc H, et al: A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 64: 1730-1739, 2012.

78. Anstee QM, Concas D, Kudo H, Levene A, Pollard J, Charlton P, Thomas HC, Thursz MR and Goldin RD: Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J Hepatol 53: 542-550, 2010.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.